Cue Biopharma
CUE
97 hedge funds and large institutions have $242M invested in Cue Biopharma in 2020 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 40 increasing their positions, 22 reducing their positions, and 7 closing their positions.
86% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 7
82% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 22
5% more funds holding
Funds holding: 92 → 97 (+5)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.08% less ownership
Funds ownership: 2.21% → 2.13% (-0.08%)
18% less capital invested
Capital invested by funds: $294M → $242M (-$52.3M)
87% less call options, than puts
Call options by funds: $359K | Put options by funds: $2.72M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
Corriente Advisors
Fort Worth,
Texas
|
+$6.36M |
| 2 |
Morgan Stanley
New York
|
+$4.04M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
+$2.62M |
| 4 |
Millennium Management
New York
|
+$2.42M |
| 5 |
Goldman Sachs
New York
|
+$2.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$18.9M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$5.39M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$2.53M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$1.29M |
| 5 |
BL
Bleichroeder LP
New York
|
-$999K |
CUE Hedge Fund Activity: Q4 2020 in Review
97 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q4 2020, worth a combined $242M — down 18% from $294M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new CUE positions and 7 closed out — a net gain of 6 holders — while 40 added to existing stakes and 22 trimmed.
The largest buyer was Corriente Advisors, adding an estimated $6.36M. The largest seller was Avoro Capital Advisors, cutting an estimated $18.9M.
- 97 institutional investors held Cue Biopharma (CUE) as of Q4 2020, up from 92 in Q3 2020.
- Funds reported $242M of Cue Biopharma stock for Q4 2020, down 18% quarter-over-quarter.
- 13 funds opened new Cue Biopharma positions in Q4 2020 and 7 closed out, a net change of +6 holders.
- The largest Cue Biopharma buyer in Q4 2020 was Corriente Advisors, an estimated $6.36M added.
- The largest Cue Biopharma seller in Q4 2020 was Avoro Capital Advisors, an estimated $18.9M sold.
Based on aggregated 13F filings for Q4 2020.